We have brought together world-class investors from both the biotech and tech fields, including venture capital firms Polaris Partners, who initially seeded CAMP4, and Andreessen Horowitz, who led our Series A round.
Our investors share our commitment to deliver on the promise of our technology, our mission to revolutionzie how medicines are discovered and developed, and our vision to create a world where a treatment for every disease is possible.
Our platform enables expansive opportunities across multiple therapeutic areas and modalities. Given the enormity of the potential, we can’t do it all alone.
We intend for our approach and unparalleled understanding of transcriptional machinery and gene expression torevolutionize how our industry approaches drug discovery and development.
In January of 2020, CAMP4 announced a collaboration with Biogen Inc. (Nasdaq: BIIB) aimed at addressing neurodegenerative and neurological diseases.
The collaboration will leverage CAMP4’s Gene Circuitry Platform™️ with the aim of identifying how to dial up or down the expression of disease-associated genes within microglial cells – the primary immune cells of the central nervous system, which are implicated in many serious neurological and neurodegenerative diseases.